{Reference Type}: Clinical Trial, Phase I
{Title}: SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
{Author}: Morgensztern D;Johnson M;Rudin CM;Rossi M;Lazarov M;Brickman D;Fong A;
{Journal}: Lung Cancer
{Volume}: 145
{Issue}: 0
{Year}: 07 2020
{Factor}: 6.081
{DOI}: 10.1016/j.lungcan.2020.04.017
{Abstract}: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma.<BR>Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study.<BR>Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response.<BR>SC-002 treatment was associated with systemic toxicity and limited efficacy.